Exploring the comparative effects of general anesthesia combined with intrathecal injection of morphine/nerve block for thoracoscopic surgery and the optimal dose of morphine

开始日期2024-11-05

申办/合作机构

The First Hospital of Harbin Medical University

ACTRN12623001309673 / Not yet recruiting临床4期IIT

The Utility of Pericapsular Nerve Group (PENG) Block versus Intrathecal Morphine for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Multicentre Triple Blinded Randomised Controlled Trial

开始日期2024-10-01

申办/合作机构-

CTRI/2024/09/073572 / Not yet recruiting临床3期IIT

Comparison Of Two Different Doses Of Intrathecal Morphine On Postoperative Analgesia In Renal Transplant Recipients. A Non-Inferiority Randomised Controlled Trial. - NIL

开始日期2024-09-18

申办/合作机构

Post Graduate Institute of Medical Education & Research

100 项与吗啡-6-葡萄糖苷酸相关的临床结果

登录后查看更多信息

100 项与吗啡-6-葡萄糖苷酸相关的转化医学

登录后查看更多信息

100 项与吗啡-6-葡萄糖苷酸相关的专利（医药）

登录后查看更多信息

56,920

项与吗啡-6-葡萄糖苷酸相关的文献（医药）

2025-03-01·NEUROPHARMACOLOGY

Paternal morphine alters offspring circulating beta-endorphin and corticosterone responses to oxycodone and cocaine

Article

作者: Isgate, Sara B ; Byrnes, Elizabeth M ; Budge, Kerri E ; Vassoler, Fair M

BACKGROUND:

The opioid epidemic is leading to increased opioid use in adolescent populations. A growing body of evidence suggests that taking opioids during adolescence can disrupt normal development and impact future offspring. This study investigates the impact of paternal morphine exposure during adolescence on the hypothalamic-pituitary-adrenal (HPA) axis and release of endorphins in the offspring.

METHODS:

Male rats were administered morphine once a day from postnatal day (PND)30-39 using an increasing dosing regimen (5-25mg/kg/day increasing every other day). They were mated during adulthood to drug naïve females. Their offspring were assessed for circulating beta-endorphin (βE) and corticosterone levels on PND30 (a timepoint prior to puberty in both sexes) in response to an acute injection of saline, oxycodone (1 mg/kg, i.p.) or cocaine (10 mg/kg, i.p.). At PND60, naïve littermates were catheterized so that a within-subjects design could be implemented to measure βE and corticosterone in response to saline, oxycodone, or cocaine.

RESULTS:

In males, βE levels in the plasma were increased in Mor-F1 males compared to Sal-F1 males regardless of the acute injection. This elevation was observed at PND30 and PND60. There were no differences in female circulating βE. In terms of corticosterone, male Mor-F1 offspring had blunted corticosterone at PND30, but elevated corticosterone in response to oxycodone at PND60. The females also tended towards lower corticosterone prior to puberty but had significantly elevated levels of circulating corticosterone following an acute cocaine injection.

CONCLUSION:

Paternal morphine exposure during adolescence induces sex- and drug-specific changes in secreted hormone responses in offspring. The alterations in βE and corticosterone levels suggest mechanisms through which adolescent opioid exposure can impact endocrine functions of future offspring. These findings contribute to the understanding of intergenerational transmission of substance use effects.

2025-03-01·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Continuous regional anesthesia with erector spinae plane catheters for patients with multiple rib fractures

Article

作者: Driver, Brian E ; Rauschenbach, Anthony ; Nguyen, Michelle ; Smoot, William ; Lee, Dan ; Dreyfuss, Andrea ; Richardson, Chad J ; Reardon, Robert F ; Martel, Marc L

INTRODUCTION:

Opioids are commonly used for acute pain management in patients with rib fractures, but their use poses known risks of addiction and respiratory depression. Regional anesthesia, namely the erector spinae plane(ESP) block, has shown promise as an alternative to opioids in case series. Our aim was to evaluate the efficacy and safety of continuous ropivacaine infusion ESP catheters performed by emergency physicians (EP) for patients with multiple unilateral rib fractures.

METHODS:

This retrospective case control study identified polytrauma patients with rib fractures in a 1-year period between 2019 and 2020 who had an ESP catheter placed by EP. The control group consisted of polytrauma patients who did not receive regional anesthesia and were matched by number of rib fractures and age. Our primary outcome was opioid use in morphine milligram equivalents per day (MMED). We compared MMED before and after catheter placement in the treatment group and overall MMED between the control and catheter group. Secondary outcomes included length of hospitalization, rate of intubation, and complications. Subgroup analysis of the same variables was performed on the group of patients whose only injury was rib fractures.

RESULTS:

The catheter group included 89 patients, matched with an equal number in the control group. Opioid use decreased from 89 to 67 MMED after catheter placement in the treatment group (P = 0.003). Overall opioid use during hospitalization did not significantly differ between treatment and control groups (P = 0.57). There was a trend toward fewer days of mechanical ventilation and shorter hospital length of stay in the catheter group in patients with isolated rib fractures, but neither of these trends reached statistical significance.

CONCLUSION:

Opioid use decreased after ESP catheter implementation and there were no meaningful complications. Although there was no significant difference in opioid use between groups, ESP catheter placement and continuous regional anesthesia by EP is a safe, reasonable adjunct to treat pain from rib fractures.

2025-03-01·NEUROPHARMACOLOGY

The cannabinoid CB2 agonist LY2828360 suppresses neuropathic pain behavior and attenuates morphine tolerance and conditioned place preference in rats

Article

作者: Wirt, Jonah L ; Saberi, Shahin A ; Hohmann, Andrea G ; Crystal, Jonathon D ; Oliva, Idaira ; Guenther, Kelsey G

Cannabinoid CB₂ agonists show promise as analgesics because they lack unwanted side effects associated with direct activation of CB₁ receptors. CB₂ receptor activation suppresses pathological pain in animal models, but the types of pain that best respond to CB₂ agonists are incompletely understood. This gap in knowledge may contribute to failures in clinical translation. We previously showed that the G protein-biased CB₂ receptor agonist LY2828360 attenuated the maintenance of neuropathic pain behavior in mouse models of inflammatory and neuropathic pain. Whether this finding generalizes to neuropathic pain induced by traumatic nerve injury or occurs in multiple rodent species remains unknown. Here we show that LY2828360 (3 and 10 mg/kg i.p.), administered acutely, reversed paclitaxel-induced mechanical hypersensitivity in male rats. By contrast, LY2828360 (10 mg/kg i.p.), administered acutely, attenuated mechanical hypersensitivity in a spared nerve injury (SNI) rat model, whereas the low dose (3 mg/kg i.p.) was ineffective. In both models, efficacy of LY2828360 was sustained following 10 days of repeated dosing. LY2828360 (3 mg/kg i.p.) also prevented development of tolerance to the opioid analgesic morphine (6 mg/kg i.p.) in rats with SNI when co-administered. LY2828360 (3 mg/kg i.p.) did not produce preference or aversion in the conditioned place preference (CPP) test in rats when administered alone but blocked CPP to morphine (6 mg/kg i.p.). Lastly, LY2828360 (3 mg/kg i.p.) did not alter the acquisition of i.v. morphine self-administration under fixed ratio 1 (FR1) and 3 (FR3) or motivation to work for morphine under a progressive ratio (PR) schedule of reinforcement.

项与吗啡-6-葡萄糖苷酸相关的新闻（医药）

2024-07-23

·Business Wire

Tersera Therapeutics LLC Announces That the 2024 Polyanalgesic Consensus Conference (PACC) Guidelines Issued Updated Guidance for Administering PRIALT

DEERFIELD, Ill.--( BUSINESS WIRE )--TerSera Therapeutics LLC announced today that the 2024 Polyanalgesic Consensus Conference (PACC) guidelines reinforce the role of non-opiate PRIALT in treating severe chronic pain. The 2024 PACC guidelines build upon prior iterations. This includes the 2016 PACC guidelines which recommend PRIALT as a first line option for neuropathic (chronic pain that occur when a health condition affects the nerves that send sensations to the brain) and nociceptive pain (pain caused by damage to body tissue). 1 The updated PACC Guidelines were published in the journal of Neuromodulation on May 16, 2024. 2 As noted in the guidelines, “proper individualized dosing is paramount for success with ziconotide.” The updated 2024 PACC guidelines discuss several crucial parameters for starting a patient successfully on PRIALT. Please refer to the full 2024 PACC Guidelines for additional information. 2 “The updated 2024 PACC guidelines provide clinicians with recommendations on how to manage PRIALT therapy for patients with severe, chronic pain,” said Gladstone C. McDowell II, MD. Dr. McDowell is the founder and former Medical Director of Integrated Pain Solutions in Columbus, Ohio and an author of the PACC guidelines. “In addition, it is beneficial to have an effective non-opioid analgesic option for this patient population. I appreciate having the ability to mitigate the potential risk of dependence and addiction for patients by using PRIALT.” Nancy Martin, MD, PharmD, Chief Medical Officer at TerSera, commented, “The PACC guidelines expert panel has continued to support PRIALT as an option for patients with severe, chronic pain who are refractory to other treatments." The International Neuromodulation Society (INS) commissioned a panel of distinguished clinical experts, and a series of Polyanalgesic Consensus Conferences produced the first guidelines after the inaugural meeting in 1999. 2 The authors of the PACC guidelines consist of an international, multidisciplinary team of experts in the intrathecal drug delivery . 1-2 PRIALT approved by the U.S. Food and Drug Administration (FDA) in 2004, is used to manage severe chronic pain in adults when other treatments do not work, stop working or cannot be tolerated. PRIALT is placed directly into the spinal fluid (termed “intrathecal” use) by a qualified physician who determines that the patient is appropriate for this procedure. PRIALT is not an opioid and is not a controlled, scheduled drug, meaning that the drug does not show the potential for dependence and subsequent abuse. 4 According to the Centers for Disease Control and Prevention (CDC), it is estimated that nearly 17 million Americans suffer from severe chronic pain of some kind. 3 Chronic pain conditions may be the result of more than one cause—damage to body tissues (nociceptive), damage to the nervous system (neuropathic), or a mix of the two. 1-2 Severe chronic pain patients are treated in a variety of ways, including use of oral opioids, transdermal opioids, physical therapy, injection therapy, spinal cord stimulation, spinal surgery, and more. When these methods do not adequately manage the individual’s pain, many doctors prescribe an intrathecal infusion treatment in which a pump is surgically implanted in the abdomen to deliver pain medication directly to the spinal cord to inhibit pain signals. In addition to PRIALT, only morphine is FDA-approved as an intrathecal (IT) infusion treatment for severe chronic pain. ABOUT TERSERA THERAPEUTICS TerSera Therapeutics is a biopharmaceutical company with a focus in oncology, acute care, and non-opioid pain management. Founded in 2016, TerSera is building new cornerstones of care through its portfolio of unique therapeutics, amplifying their ability to deliver meaningful outcomes for patients. For more information about TerSera Therapeutics, please visit tersera.com . ABOUT PRIALT 4 PRIALT intrathecal solution is an N-type calcium channel antagonist used to treat severe chronic pain in patient’s refractory to other treatments. PRIALT was first approved in 2004; PRIALT is available as a 1- or 5-mL vial of 100 mcg/mL solution or a 20 mL vial of 25 mcg/mL solution. INDICATION PRIALT is a prescription medicine used to treat severe chronic pain in adults who cannot take other treatments or when other treatments do not work, stop working, or cause bothersome side effects. PRIALT can only be delivered by or under the direction of a doctor who injects the medicine into your spinal fluid through a special device (a procedure called intrathecal infusion) and should only be used in patients who are appropriate for the procedure. IMPORTANT SAFETY INFORMATION PRIALT may cause serious side effects including psychiatric (mental) symptoms and problems thinking (confusion, memory problems, speech difficulties). The doctor should be called immediately if, while taking PRIALT, you are confused or disoriented, are less alert, see or hear things that are not real (hallucinations), have changes in mood or consciousness. Your doctor may stop your treatment with PRIALT, give you other medicines, or require you to be hospitalized if you experience any of these symptoms. You should not be given PRIALT if you: are allergic to PRIALT or any of its ingredients have a condition or are receiving a treatment that would cause an injection in your spinal fluid to be unsafe have or had a mental illness called psychosis (a loss of contact with reality), usually including delusions (false beliefs about what is taking place or who one is) or hallucinations (seeing or hearing things that are not real) PRIALT may cause or worsen depression, which increases the risk of suicide. People 65 years of age and older have a higher risk for confusion with PRIALT. Taking certain other medicines along with PRIALT may raise the risk of having problems with thinking or alertness. Tell your doctor about all the medicines you are taking. Meningitis (inflammation of the protective membranes covering the brain and spinal cord) or other infections can happen if the infusion device becomes contaminated. Tell your doctor right away if you have fever, headache, stiff neck, changes in mental status (feeling tired, confused, disoriented), nausea, vomiting, and/or seizures as these may be symptoms of developing meningitis. PRIALT may cause unconsciousness or reduced mental alertness. Avoid activities where you need to be alert, awake, and have full control of your body (activities like operating machinery or driving a car) during treatment with PRIALT. Tell the doctor if you experience new or worsening muscle pain, soreness, weakness or if your urine is dark in color as this could be a sign of rare but serious muscle side effects. You should also tell the doctor if you are pregnant, plan to become pregnant or if you are breastfeeding. The most common side effects of PRIALT include dizziness, nausea, confusion, and uncontrolled eye movements. These are not all the possible side effects of PRIALT. Talk to your doctor about any side affects you may be experiencing. To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch . You may also contact TerSera Therapeutics at 1-844-334- 4035 or medicalinformation@tersera.com . Please see Important Safety Information above and full Prescribing Information, including BOXED Warning. References 1. Deer T.R., Pope J.E., Hayek S., Lamer T.J., Veizi I.E., Erdek M., Wallace M.S., Grider J.S., Levy R.M., Prager J., Rosen S.M., Saulino M., Yaksh T.L., De Andres J.A., Abejon Gonzalez D.,Vesper J., Schu S.,Simpson B.,Mekhail N. 2017. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation 2017; E-pub ahead of print. DOI:10.1111/ner.12579 2. Deer T.R., Hayek S.M., Grider J.S., Hagedorn J.M., McDowell G.C., Kim P., Dupoiron D., Goel V., Duarte R., Pilitsis J.G., Leong M.S., De Andrés J., Perruchoud C., Sukumaran H., Abd-Elsayed A., Saulino M., Patin D., Poree L.R., Strand N., Gritsenko K., Osborn J.A., Dones I., Bux A., Shah J.M., Lindsey B.L., Shaw E., Yaksh T.L., Levy R.M. 2024. The Polyanalgesic Consensus Conference (PACC)®: Intrathecal Drug Delivery Guidance on Safety and Therapy Optimization When Treating Chronic Non-cancer Pain. Neuromodulation 2024; -:1–33. 3. Rikard, S. M., Strahan, A. E., Schmit, K. M., & Guy Jr., G. P. (2023). Chronic Pain Among Adults — United States, 2019–2021. MMWR Morbidity and Mortality Weekly Report , 72(15), 433–438. 4. PRIALT ® (ziconotide). Prescribing information. TerSera Therapeutics LLC. PRIALT is a registered trademark of TerSera Therapeutics LLC ©2024TerSera Therapeutics LLC. All rights reserved. PRI-P-1170v2 (07/2024)

上市批准

2024-03-12

·Business Wire

CHLA Researchers Find That Length of Opioid Treatment for Hospitalized Infants Differs by Institution and Geography

LOS ANGELES--( BUSINESS WIRE )--Opioids such as fentanyl and morphine can provide effective pain relief for infants with complex medical conditions when used carefully. But who decides what careful actually means? In a study published in JAMA Network Open, researchers at Children’s Hospital Los Angeles found the opioid treatment that critically ill, hospitalized infants received depended on their location. The length of time the infants were prescribed opioids differed by geographic region across the U.S.— the Northeast, South, Midwest or West. And up to 16% of this variability in infant opioid prescriptions and 20% of the methadone prescriptions—the medication used to help wean infants safely from opioids—depended on the individual hospital. “Opioid prescribing patterns for adults have been well-studied, but this study is the first to examine inpatient opioid prescribing patterns in critically ill infants on a national scale,” says Olivia A. Keane, MD, lead author on the paper. “Our study reports wide variation in opioid prescribing and thus exposure of infants to opioids across institutions.” Dr. Keane notes that the lack of standardized guidelines for opioid prescribing in infants can lead to significant differences in hospitalization length of stay, days on mechanical ventilation, days of IV nutrition, and can also impact healthcare costs. Pain relief vs. long-term effects Appropriate dosing of opiates requires a delicate balance. There is the obvious clinical need to ease a baby’s pain, and without sufficient pain relief, infants can experience more complicated recoveries and poorer clinical outcomes after surgeries and intubation. “Additionally, prolonged opioid exposure in high-risk hospitalized infants has been implicated in worsening neurodevelopmental outcomes,” Dr. Keane says. “Thus, lack of standardization and the significant variation demonstrated by our study may put some infants at higher risk of poor long-term outcomes.” Children’s Hospital Los Angeles researchers and their collaborators conducted a retrospective study of 132,658 high-risk infants under 1 year old who were treated in 47 different children’s hospitals around the U.S. The most common high-risk diagnosis was congenital heart disease (65%), 30% of infants were born prematurely, and over half underwent surgery. During their hospital stay, 76% of infants were prescribed opioids such as fentanyl, morphine and hydromorphone, and about 8% received methadone. But infants’ exposure to opioids and methadone post-treatment varied significantly by hospital and location. “Our findings reinforce the need to establish national standards for best practices in opioid prescription in infants,” says Lorraine Kelley-Quon, MD, MSHS , pediatric surgeon and senior study author who directs the Health Outcomes and Policy Effects Laboratory at Children’s Hospital Los Angeles. About Children’s Hospital Los Angeles Founded in 1901, Children’s Hospital Los Angeles is at the forefront of pediatric medicine and is the largest provider of hospital care for children in California. Children’s Hospital is home to renowned experts who work together across disciplines to deliver inclusive and compassionate care, and drive advances that set pediatric standards across the nation and around the globe. Children’s Hospital Los Angeles provides a level of care to its diverse population of children that is among the best in the world. The hospital is consistently ranked in the top 10 in the nation on U.S. News & World Report’s Honor Roll of Best Children’s Hospitals, including No. 1 in California and No. 1 in the Pacific U.S. region. Children’s Hospital Los Angeles embraces its mission to create hope and build healthier futures. Children’s Hospital Los Angeles is among the top 10 children’s hospitals for National Institutes of Health funding. The Saban Research Institute of Children's Hospital Los Angeles supports the full continuum of research, allowing physicians and scientists to translate discoveries into treatments and bring answers to families faster. The pediatric academic medical center also is home to one of the largest training programs for pediatricians in the United States. And the hospital’s commitment to building strong communities is evident in CHLA’s efforts to fight food insecurity, enhance health education and literacy, and introduce more people to careers in health care. To learn more, follow CHLA on Facebook , Instagram , LinkedIn , YouTube and X , formerly known as Twitter, and visit CHLA.org/blog .

2023-01-05

·米内网

人福医药厉害了！18款新药接踵而至，8个首仿抢攻千亿市场，27个爆款冲刺上市

精彩内容2022年已完成了它的历史使命，人福医药在去年收获了首款中药1类新药广金钱草总黄酮胶囊，标志着公司正式入局泌尿系统疾病中成药市场；儿童罕见病用药氯巴占片首仿获批，现为独家产品；盐酸羟考酮缓释片首仿获批，终结了原研药独占市场的局面……回顾最近三年，人福医药逐步实现从“跟跑”、“并跑”到“领跑”的重大跨越，创新药、首仿药陆续上市，研发实力不断提升，公司在研的生物药1类新药已进入III期临床，27个高端仿制药也在冲刺上市，2023年公司有望再攀高峰。创新药大爆发！4款1类新药已亮相，14款在研新药全力出击表1：人福医药2020-2022年获批上市的新药（不含新适应症）来源：米内网中国申报进度（MED）数据库近三年，人福医药的创新之路从“聚焦”拓展至“多面”，2020-2021年各有1款神经系统1类新药获批，进一步增强公司在细分领域的领导地位。2022年9月，公司在泌尿系统疾病中成药市场有了新的突破。用于输尿管结石中医辨证属湿热蕴结证者，功能主治为清热祛湿、利尿排石的广金钱草总黄酮胶囊获批上市，据悉，该新药是参考我国传统中医药治疗经验，结合广金钱草长期的临床应用经验，采用现代化工艺分离纯化广金钱草总黄酮有效部位，以该有效部位组方研制开发成的中药1.2类新药。从目前情况来看，人福医药每年均有1类新药获批上市，公司的研发实力处于行业前列。表2：人福医药部分已进入临床阶段的重磅新药来源：米内网中国临床试验数据库、公司公告等米内网数据显示，人福医药目前有10多款新药在研，7款已进入临床阶段的1类新药备受市场瞩目。重组质粒-肝细胞生长因子注射液已进入III期临床，有望成为公司首款上市的生物药1类新药；化药1类新药方面，HWH340片在II期临床阶段，吗啡-6-葡萄糖苷酸注射液、HW021199片、RF-A089胶囊、HWH486胶囊以及RFUS-144注射液均在I期临床阶段……上述1类新药除了涉及镇痛领域，还拓展至肿瘤、类风湿性关节炎等领域。改良新药方面，人福医药瞄准神经系统大品种进行高端剂型创新，右美托咪定透皮贴剂、氨酚氢可酮缓释片、右美托咪定透皮贴剂(Ⅱ)、舒芬太尼透皮贴剂、注射用RF16001、盐酸右美托咪定鼻喷雾剂已进入I期临床阶段。此外，用于治疗轻型复发性阿弗他溃疡的复方新药复方西地碘含片的II期临床也正在进行中。人福医药年报数据显示，2020年公司的研发投入为9.37亿元，同比增长23.36%；2021年研发投入增至10.61亿元，同比增长12.92%……公司不断加码研发投入，同时迎来了丰收期，随着上述在研新药的临床进展不断推进，公司的产品矩阵将日益强大。三年拿下20个新品，首仿聚焦千亿市场！27个高端仿制药冲刺上市2020-2022年三年间，人福医药共拿下了20个仿制药新品，其中神经系统药物占8个，心脑血管系统药物占3个，肌肉-骨骼系统药物占3个，消化系统及代谢药、生殖泌尿系统和性激素类药物、全身用抗感染药物各占2个。表3：人福医药2020-2022年获批上市的仿制药（按批文统计）来源：米内网中国申报进度（MED）数据库公司在拳头领域神经系统拿下了5个国内首仿，涉及盐酸阿芬太尼注射液（2020年）、咪达唑仑口服溶液（2021年）、盐酸安非他酮缓释片(Ⅱ)（2021年）、氯巴占片（2022年，现为独家产品）、盐酸羟考酮缓释片（2022年），在心脑血管系统拿下盐酸普萘洛尔口服溶液的国内首仿（2021年），公司在两大千亿市场新添了多员猛将。此外，公司还入局抢食多个大品种，盐酸二甲双胍缓释片、恩替卡韦片、富马酸丙酚替诺福韦片、丙泊酚中/长链脂肪乳注射液、非那雄胺片2021年在三大终端6大市场（统计范围见文末）合计销售额已超过10亿元，而琥珀酸美托洛尔缓释片更是超过30亿元。凭借公司的品牌效应，新品上市也能抢下一席之地，同时也能与公司的其他产品形成更好的协同。有消息指，2022版国家医保谈判或将在本月进行，盐酸阿芬太尼注射液、盐酸安非他酮缓释片(Ⅱ)、盐酸美金刚缓释胶囊、舒更葡糖钠注射液均已通过形式审查，为目录外条件1（即新获批上市的产品），而非独家产品将进行竞价，人福医药最终有多少款产品进入新医保目录，我们静待官宣。表4：人福医药2020-2022年申报上市并在审的仿制药注：公司已有上市批文的产品用*表示来源：米内网中国申报进度（MED）数据库米内网数据显示，人福医药2020-2022年申报上市、目前正在审评审批中的仿制药有32个，其中27个为新品（即首次获批）。正在冲刺上市的新品较多为神经系统药物占了8个，抗肿瘤和免疫调节剂占4个，全身用抗感染药物、消化系统及代谢药、心脑血管系统药物各占3个，肌肉-骨骼系统、血液和造血系统药物各占2个，皮肤病用药、全身用激素类制剂(不含性激素和胰岛素)各占1个。人福医药除了在创新药上拓展更多领域，在高端仿制药的梯队布局中也更全面、更合理。神经系统药物盐酸氢吗啡酮缓释片和布洛氢可酮片目前仅有人福医药提交仿制上市申请，大概率能拿下首仿。抗肿瘤和免疫调节剂枸橼酸托法替布缓释片、恩杂鲁胺软胶囊、乙磺酸尼达尼布软胶囊、麦考酚钠肠溶片，神经系统药物利丙双卡因乳膏、氨酚羟考酮片、盐酸艾司氯胺酮注射液，消化系统及代谢药富马酸伏诺拉生片、艾地骨化醇软胶囊、西甲硅油乳剂，心脑血管系统药物ω-3脂肪酸乙酯90软胶囊、非诺贝特酸胆碱缓释胶囊，皮肤病用药地奈德乳膏，全身用抗感染药物盐酸阿比多尔片，上述14个产品有望争取国产第二家或第三家获批，前三家获批有先发优势，将助力公司尽快抢占市场高地。49个过评产品亮眼！领跑神经系统过评榜，重磅产品备战新国采一致性评价方面，人福医药过评（含视同过评）的产品数量达49个，作为公司的拳头领域，人福医药在神经系统药物过评榜名列前茅。截至目前，已过评的神经系统药物达136个（按产品名统计），人福医药以20个过评产品排在过评企业TOP1，华海药业及扬子江药业均以17个过评产品并列企业TOP2。表5：人福医药已过评的产品情况来源：米内网一致性评价进度数据库20个产品拿下首家过评，涉及盐酸苯海拉明片、布洛芬软胶囊（独家过评）、萘普生钠片（独家过评）、枸橼酸芬太尼注射液（独家过评）、氯巴占片（独家过评）、咪达唑仑口服溶液、盐酸阿芬太尼注射液、盐酸安非他酮缓释片、盐酸安非他酮缓释片(Ⅱ)、盐酸纳布啡注射液、盐酸哌替啶注射液（独家过评）、盐酸羟考酮缓释片（独家过评）、盐酸氢吗啡酮注射液（独家过评）、盐酸左布比卡因注射液、注射用盐酸瑞芬太尼、格列齐特缓释片、维生素B2片、酒石酸美托洛尔注射液、盐酸普萘洛尔口服溶液、氟马西尼注射液。12个产品拿下第二或第三家过评，涉及复方磺胺甲噁唑片、盐酸克林霉素胶囊、盐酸乙胺丁醇片、异烟肼片、对乙酰氨基酚片、枸橼酸舒芬太尼注射液、卡马西平片、咪达唑仑注射液、盐酸罗哌卡因注射液、米非司酮片、米索前列醇片、维生素B6片。人福医药积极参加国家集中带量采购，从第二批到第七批（不含第六批胰岛素专项）共10个产品中标。在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，公司第二批国采中标的对乙酰氨基酚片2022上半年的市场份额涨至37.44%，第三批国采中标的维生素B6片2022上半年的市场份额涨至15.40%，第四批国采中标的格列齐特缓释片2022上半年的市场份额涨至25.53%，国采助力公司提升市场竞争力。随着2023年拉开序幕，第八批国采再次受到热烈关注，目前人福医药已过评且暂未纳入国采的产品中，氟马西尼注射液、盐酸左布比卡因注射液、舒更葡糖钠注射液、维生素B2片过评企业总数≥4家。崭新的2023年已经到来，2022版国家医保目录调整、第八批国采将是今年上半年的行业大事，正在快速转型的人福医药又将如何应战，我们拭目以待。数据来源：米内网数据库、公司年报等注：米内网《中国三大终端6大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至2022年12月31日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

临床3期临床2期上市批准申请上市

100 项与吗啡-6-葡萄糖苷酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	吗啡-6-葡萄糖苷酸	-	DB06409

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
术后疼痛	临床3期	捷克	Paion UK Ltd.	2005-11-01
术后疼痛	临床3期	法国	Paion UK Ltd.	2005-11-01
术后疼痛	临床3期	德国	Paion UK Ltd.	2005-11-01
术后疼痛	临床3期	荷兰	Paion UK Ltd.	2005-11-01
术后疼痛	临床3期	波兰	Paion UK Ltd.	2005-11-01
术后疼痛	临床3期	英国	Paion UK Ltd.	2005-11-01
中度疼痛	临床1期	中国	宜昌人福药业有限责任公司	2019-07-01
重度疼痛	临床1期	中国	宜昌人福药业有限责任公司	2019-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Cureus	临床3期	-	74	Intrathecal Morphine	範鹽簾蓋願艱廠網餘積(鹽膚膚壓鏇遞構選範蓋) = 襯築鏇構鹹鏇壓獵獵衊衊獵顧夢膚構遞構繭鏇 (築憲醖齋餘繭獵窪夢膚 ) 更多	积极	2024-07-17
				Intrathecal Morphine (Erector Spinae Plane Block)	範鹽簾蓋願艱廠網餘積(鹽膚膚壓鏇遞構選範蓋) = 糧鑰鹹襯襯糧窪鹽膚餘衊獵顧夢膚構遞構繭鏇 (築憲醖齋餘繭獵窪夢膚 ) 更多
NCT00701909 (CTgov)	临床3期	疼痛 \| 恶心 \| 幻觉 ... 更多	12	Morphine+Ketamine (Morphine Plus Ketamine)	窪醖窪鹽壓夢夢製觸製(鹹觸齋壓齋糧鏇構觸築) = 製夢壓範鏇窪鏇遞獵構糧淵積餘齋繭積淵鬱艱 (繭築鹽餘鹹遞鬱艱壓鑰, 窪鬱夢壓網構夢願夢範 ~ 鏇窪構遞夢襯憲構遞窪) 更多	-	2024-03-26
				Morphine (Morphine Plus Saline)	窪醖窪鹽壓夢夢製觸製(鹹觸齋壓齋糧鏇構觸築) = 憲顧窪獵醖願鬱簾積範糧淵積餘齋繭積淵鬱艱 (繭築鹽餘鹹遞鬱艱壓鑰, 積憲醖蓋繭築願製餘網 ~ 襯齋齋艱憲醖廠鬱鹹衊) 更多
NCT02223377 (SAME-Day, CTgov)	N/A	镇痛 \| 术后恶心呕吐 \| 呕吐	402	Morphine (Morphine)	衊積衊願獵選壓艱糧淵(鑰顧糧鏇範築蓋鏇願觸) = 壓網鑰襯鹹鬱夢壓憲鏇範顧餘築膚鏇艱壓餘襯 (顧鏇鹽鏇餘鹹簾網廠鬱, 憲顧餘顧廠鏇製憲齋齋 ~ 構糧蓋範窪範觸製繭醖) 更多	-	2023-12-11
				Hydromorphone (Hydromorphone)	衊積衊願獵選壓艱糧淵(鑰顧糧鏇範築蓋鏇願觸) = 夢窪艱齋襯膚壓襯淵鹽範顧餘築膚鏇艱壓餘襯 (顧鏇鹽鏇餘鹹簾網廠鬱, 獵衊糧廠襯構築餘鑰積 ~ 鬱鏇廠構鹹淵獵淵獵範) 更多
WSC2023	N/A	慢性阻塞性肺疾病	-	Sustained-release morphine 20mg	襯襯鹹選淵襯範襯衊範(積鏇衊膚範醖壓衊淵遞) = 壓鬱構齋蓋網築積膚憲齋鏇鹹夢膚築願鬱願廠 (鬱膚願築網鏇顧夢衊夢 ) 更多	-	2023-10-23
				Placebo	襯襯鹹選淵襯範襯衊範(積鏇衊膚範醖壓衊淵遞) = 餘製醖艱廠構齋獵築簾齋鏇鹹夢膚築願鬱願廠 (鬱膚願築網鏇顧夢衊夢 ) 更多
NCT01900847 (CTgov)	N/A	急性疼痛	17	placebo+morphine (Morphine and Placebo)	廠糧遞齋齋憲築襯遞蓋(製齋衊壓構繭積壓廠積) = 壓窪窪艱範壓鏇淵願網築顧齋憲齋蓋鏇簾簾獵 (鹹衊襯夢築蓋鹽繭觸齋, 齋憲繭膚襯觸窪艱窪糧 ~ 鹽淵膚簾範憲繭遞觸壓) 更多	-	2023-07-17
				morphine+Ketamine (Morphine and Ketamine)	廠糧遞齋齋憲築襯遞蓋(製齋衊壓構繭積壓廠積) = 鬱鏇積憲顧範襯顧鑰簾築顧齋憲齋蓋鏇簾簾獵 (鹹衊襯夢築蓋鹽繭觸齋, 襯構襯鑰衊網鬱築選衊 ~ 選鬱鬱鏇衊糧膚積鹽醖) 更多
EHA2023	N/A	肿瘤	-	Oxycodone	觸膚窪築顧簾衊選願壓(鹽觸築壓選艱膚餘糧襯) = 餘窪鏇襯憲積鏇齋觸膚繭鏇衊顧遞築積鏇獵憲 (鑰顧鏇窪憲糧憲選願鑰 )	-	2023-06-08
				Morphine	觸膚窪築顧簾衊選願壓(鹽觸築壓選艱膚餘糧襯) = 膚夢願繭憲構構觸顧艱繭鏇衊顧遞築積鏇獵憲 (鑰顧鏇窪憲糧憲選願鑰 )
NCT02456909 (PCA Cues, CTgov)	N/A	术后疼痛	176	Patient-Controlled Analgesia pump with Cues+morphine (Cues)	簾蓋顧範膚顧選糧範鏇(餘構淵積範夢夢淵蓋鹽) = 築鬱憲餘襯蓋繭膚鬱淵艱顧蓋醖醖獵窪積網鹹 (鑰蓋獵廠繭鹹窪鏇獵構, 齋製淵顧鏇鏇鏇艱鏇簾 ~ 獵遞衊鏇網繭醖醖繭遞) 更多	-	2021-09-08
				Patient-Controlled Analgesia pump without Cues+morphine (No Cues)	簾蓋顧範膚顧選糧範鏇(餘構淵積範夢夢淵蓋鹽) = 願遞繭廠餘觸艱襯廠鬱艱顧蓋醖醖獵窪積網鹹 (鑰蓋獵廠繭鹹窪鏇獵構, 簾廠觸獵構構淵選網鹽 ~ 艱願艱網範願鹹構遞鏇) 更多
P-122 (ESMO_GI2021)	N/A	癌症疼痛 nicotine \| opioid receptors	96	morphine (Smokers)	鏇觸範窪襯衊網構淵醖(鏇蓋壓窪製艱衊餘範齋) = 憲廠觸網衊鹹觸鏇淵襯築築網範廠壓醖窪衊衊 (壓鹹齋齋淵獵簾範鹽範 ) 更多	积极	2021-07-03
				morphine (Non-smokers)	鏇觸範窪襯衊網構淵醖(鏇蓋壓窪製艱衊餘範齋) = 獵選鹽簾積遞膚繭構艱築築網範廠壓醖窪衊衊 (壓鹹齋齋淵獵簾範鹽範 ) 更多
NCT01977898 (CTgov)	N/A	硬膜后腰椎穿刺后头痛 \| 脑脊液漏 \| 头痛	68	morphine (Morphine)	鬱鏇構齋簾鏇積衊淵窪(淵壓衊網鬱遞選願鏇選) = 鹹艱鏇觸膚製觸蓋憲觸鑰淵簾願糧積積觸範製 (膚鏇膚願鹹遞顧壓廠夢, 鑰築鬱築鬱築觸憲鹽鹹 ~ 鹽簾網鏇齋蓋糧觸齋醖) 更多	-	2021-04-02
				saline (Saline)	鬱鏇構齋簾鏇積衊淵窪(淵壓衊網鬱遞選願鏇選) = 蓋糧築襯願艱夢窪鏇淵鑰淵簾願糧積積觸範製 (膚鏇膚願鹹遞顧壓廠夢, 鹽鹹憲製構鏇膚構網繭 ~ 壓蓋鏇範鹽製獵夢糧艱) 更多